Strs Ohio Takes $21.81 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Strs Ohio has acquired a new position in Regeneron Pharmaceuticals, purchasing 34,381 shares valued at approximately $21.81 million during the first quarter.
• Regeneron Pharmaceuticals recently reported earnings of $12.89 per share for the quarter, exceeding expectations, with revenue rising to $3.68 billion.
• The company declared a quarterly dividend of $0.88 per share, reflecting a yield of 0.6% and an annualized payout ratio of 8.87%.

Strs Ohio purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 34,381 shares of the biopharmaceutical company's stock, valued at approximately $21,805,000.

A number of other hedge funds also recently made changes to their positions in the stock. Adirondack Trust Co. boosted its stake in shares of Regeneron Pharmaceuticals by 4.2% in the 1st quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock valued at $286,000 after purchasing an additional 18 shares in the last quarter. Kingswood Wealth Advisors LLC boosted its stake in shares of Regeneron Pharmaceuticals by 1.8% in the 1st quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company's stock valued at $681,000 after purchasing an additional 19 shares in the last quarter. Creative Financial Designs Inc. ADV boosted its stake in shares of Regeneron Pharmaceuticals by 9.5% in the 1st quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company's stock valued at $139,000 after purchasing an additional 19 shares in the last quarter. Private Trust Co. NA boosted its stake in shares of Regeneron Pharmaceuticals by 13.1% in the 1st quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company's stock valued at $104,000 after purchasing an additional 19 shares in the last quarter. Finally, Proficio Capital Partners LLC boosted its stake in shares of Regeneron Pharmaceuticals by 6.2% in the 1st quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company's stock valued at $207,000 after purchasing an additional 19 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Down 1.4%

Regeneron Pharmaceuticals stock opened at $560.00 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,170.58. The firm has a 50 day moving average price of $564.61 and a two-hundred day moving average price of $579.66. The firm has a market cap of $59.35 billion, a price-to-earnings ratio of 14.11, a PEG ratio of 1.90 and a beta of 0.35.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.30 billion. During the same quarter last year, the business earned $11.56 EPS. The company's revenue was up 3.6% compared to the same quarter last year. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were issued a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.87%.

Analyst Ratings Changes

REGN has been the topic of a number of research analyst reports. UBS Group restated a "neutral" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Raymond James Financial upgraded shares of Regeneron Pharmaceuticals to a "moderate buy" rating in a research report on Tuesday, September 2nd. BMO Capital Markets lifted their target price on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a research report on Monday, August 4th. JPMorgan Chase & Co. cut their target price on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research report on Monday, June 9th. Finally, Citigroup reiterated a "buy" rating and set a $650.00 target price on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Three analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $817.67.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.